Table 1.
Clinical trials utilizing IDH and Hh pathway inhibitors in Chondrosarcoma.
| AGENTS | STUDY DESIGN/PHASE | # of PATIENTS | PRIMARY EFFICACY ENDPOINT | REFERENCE |
|---|---|---|---|---|
| CB-839 (Glutaminase inhibitor) | Phase I | n=41 | Safety/Efficacy | NCT02071862 |
| Metformin/Chloroquine | Phase IB/II | n=38 | Rate of disease control = 50% | NCT02496741 (29) |
| GDC-0449 (Hedgehog inhibitor) | Phase II | n=45 | 6 month clinical benefit rate | NCT01267955 |
| IPI-926 | Phase II | n=105 | PFS, OS, ORR | NCT01310816 |
| AG-221 (IDH2 inhibitor) | Phase I/II | n=21 | Safety/Dose escalation | NCT02273739 |
| AG-120 (IDH1 inhibitor | Phase I | n=170 | Safety/Dose escalation | NCT02073994 (16) |